SCHEDULE: Coastlands Capital Takes 9.99% Stake in X4 Pharmaceuticals

Coastlands Capital and related entities report a 9.99% beneficial ownership in X4 Pharmaceuticals following a recent private placement.

Summary

• Coastlands Capital LP and related entities, including Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry, jointly filed a Schedule 13D regarding their ownership in X4 Pharmaceuticals, Inc.
• The reporting persons collectively beneficially own 2,479,645 shares of Common Stock, representing 9.99% of the outstanding shares.
• This percentage is calculated based on 11,408,357 shares outstanding as of August 4, 2025, plus 11,040,776 shares issued in a private placement that closed on August 13, 2025.
• Coastlands purchased a pre-funded warrant exercisable for 7,047,216 shares of Common Stock for $9,999,999.50 as part of the August 2025 Financing.
• The reporting persons are subject to a beneficial ownership blocker, preventing them from exercising the pre-funded warrant to the extent that it would cause their beneficial ownership to exceed 9.99%.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are changes in management, the investment by Coastlands Capital suggests confidence in the company's future.

Positives

• Coastlands Capital's investment signals confidence in X4 Pharmaceuticals.
• The August 2025 Financing provides X4 Pharmaceuticals with additional capital.
• Coastlands Capital has entered into a resale registration rights agreement, which allows them to resell their shares of common stock.

Negatives

• The filing indicates the termination of both the Chief Executive Officer and Chief Financial Officer of X4 Pharmaceuticals.
• The beneficial ownership blocker limits Coastlands Capital's ability to exercise its pre-funded warrants.

Risks

• The Reporting Persons may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management or the board of directors of the Company with respect to the business and affairs of the Company and may from time to time consider pursuing or proposing such matters with advisors, the Issuer or other persons.
• The pre-funded warrant held by the Reporting Persons is exercisable at any time after its original issuance. Exercise of each pre-funded warrant is prohibited if, as a result of such exercise, the holder, together with its affiliates and other persons whose beneficial ownership would be aggregated with the holder's for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Blocker").

Future Outlook

The Reporting Persons may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management or the board of directors of the Company with respect to the business and affairs of the Company and may from time to time consider pursuing or proposing such matters with advisors, the Issuer or other persons.

Industry Context

The investment by Coastlands Capital reflects ongoing investor interest in the biotechnology and pharmaceutical sectors, particularly in companies like X4 Pharmaceuticals that are focused on developing novel therapies.

Comparison to Industry Standards

• Comparable investments in similar-stage biotech companies often involve institutional investors taking significant stakes to influence corporate strategy and drug development.
• The 9.99% ownership stake is a common threshold, as exceeding 10% may trigger additional regulatory scrutiny and reporting requirements.
• Other comparable companies include [Placeholder Company 1] and [Placeholder Company 2], which have seen similar investments from hedge funds and private equity firms.

Management Changes

Stakeholder Impact

• Shareholders: The investment by Coastlands Capital could increase investor confidence.
• Employees: Changes in management may create uncertainty among employees.
• Customers: The financing could support continued development and commercialization efforts.
• The August 2025 Financing and associated management changes could impact the company's strategic direction and operational efficiency.

Next Steps

• Coastlands Capital may exercise its pre-funded warrants, subject to the beneficial ownership blocker.
• The Issuer will file a registration statement covering the resale of certain shares of Common Stock held by the Reporting Persons.
• The Reporting Persons may seek to influence management or the board of directors of the Company with respect to the business and affairs of the Company.

Key Dates

Recommendation

The investment by Coastlands Capital is a positive sign, but the management changes introduce uncertainty. A hold recommendation is appropriate until the impact of these changes becomes clearer.

Keywords

X4 Pharmaceuticals, Coastlands Capital, Schedule 13D, Beneficial Ownership, Private Placement, Pre-funded Warrant, Investment